Annual cost of lymphedema treatment fell $12,000, study found
by Mike_in_Co on Thu Nov 18, 2010 09:12 PM
I thought this might benefit some people:
The American Society of Clinical Oncology recently published its Clinical Cancer Advances 2010 and hailed a new drug combination, FOLFIRINOX as being the most significant advance for pancreatic cancer this year.
The study’s authors, presenting at ASCO 2010, reported 48% of patients on FOLFIRINOX were alive after 1 year compared to 20% on the gemcitabine arm and, for the first time in a study involving patients with metastatic pancreatic cancer, a median overall survival of 11.1 months was obtained on the FOLFIRINOX arm.
When you track a discussion, you will get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to track this discussion?
If you stop tracking this discussion, you will no longer get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to stop tracking this discussion?
If you were considering traveling for cancer treatment, which headline would you find more interesting?
Destination: HOPE. Cancer care that is worth the trip.
Over 84% of our patients travel to our hospital from another state
Neither headline is interesting
We care about your feedback. Let us know how we can improve your CancerCompass experience.